Recently, Precision ADVANCE’s Anshul Mangal moderated “Considerations for Early-Stage Gene Therapy Start-Ups: From Clinical Development to Manufacturing to Commercialization,” at the Gene Therapy for Rare Disorders virtual conference.

Congratulations to Richard Macaulay on his well-attended presentation “The New SMC-Ultra-Orphan Pathway: HTA Best Practice for Very Rare Diseases?” at Virtual ISPOR 2021. Did you miss Richard’s presentation?

Clare Sarvary Fourrier, SVP of Operational Strategy (EU) for Precision for Medicine moderates this panel discussion with industry experts to share perspectives on the current state of the cell and gene therapy industry and provide key insights in shortening time-to-market for advanced therapies.

Attending Virtual ISPOR 2021 May 17-20? PRECISIONadvisors and PRECISIONheor will be attending with multiple posters, presentations, and workshops. Three posters and one presentation will have a special focus on Orphan diseases. Stay tuned for valuable insights from our experts that you won’t want to miss!

Directly following the cell therapy panel discussion in part 1, Precision experts Phil Cyr, Deb Phippard and David Parker, and Project Pharma’s Tony Khoury joined C-Suite leaders from advanced therapy companies for “Considerations for the Clinical Development of Cell & Gene Therapies.” Part 2- Gene Therapy.